Summit Therapeutics (NASDAQ:SMMT) traded higher in the premarket on Wednesday after Citi upgraded the stock to Buy from Neutral, becoming the latest brokerage to issue a bullish view on the cancer ...

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (NasdaqGM:SMMT) from Neutral to Buy. As of March 18, 2025, the average one-year price target for ...

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” ...